Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Unless you’ve been living on another planet over the past few years, you have heard of and probably know several people that ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

A year ago, Eli Lilly & Co. was poised to become the first pharmaceutical company to register a trillion-dollar market ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...